Table 1.
Characteristics of Patients at Baseline (Entry)
| Ledipasvir/Sofosbuvir for 8 Weeks (N = 27) |
|
|---|---|
| Male sex, n (%) | 27 (100) |
| Median age, y (IQR) | 46 (38–50) |
| White, non-Hispanic, n (%) | 11 (41) |
| Black, non-Hispanic, n (%) | 5 (19) |
| Hispanic or Latino (regardless of race), n (%) | 9 (33) |
| Asian or Pacific Islander, n (%) | 2 (7) |
| Intravenous drug use, n (%) | |
| Current | 1 (4%) |
| Previous | 4 (15%) |
| Reported history of STI, n (%) | 11 (41) |
| IL28B CC favorable genotype, n (%) | 16 (59) |
| HCV genotype, n (%) | |
| 1a | 23 (85) |
| 1b | 3 (11) |
| 4 | 1 (4) |
| First HCV infection, n (%) | 22 (81) |
| Median HCV RNA load, IU/mL (IQR) | 1 490 000 (32 500-3 560 000) |
| Median HCV RNA load, log10 IU/mL (IQR) | 6.17 (4.51–6.55) |
| HCV RNA load ≥ 6 million IU/mL, n (%) | 6 (22) |
| Median time (days) from first laboratory evidence of acute infection (IQR) | 116 (98–156) |
| Median CD4, cells/µL (IQR) | 561 (441–698) |
| HIV-1 RNA <50 copies/mL, n (%) | 27 (100) |
| Median ALT, mg/dL (IQR) | 133 (47–393) |
| Median AST, mg/dL (IQR) | 83 (35–224) |
| Median total bilirubin, mg/dL (IQR) | 0.60 (0.50–1.20) |
| Median creatinine, mg/dL (IQR) | 0.96 (0.88–1.15) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IL28B, interleukin 28B; IQR, interquartile range; STI, sexually-transmitted infection.